Back to results
US 2021/0275558 A1Published application
Methods for treating, pharmaceutical compositions and uses thereof
AssigneesBoehringer Ingelheim International GmbH, Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin
InventorsMaximilian Von Eynatten, Oliver Gross, Sibylle Jenny Hauske
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods, pharmaceutical compositions and uses thereof for treating and alleviating Alport syndrome, various aspects and symptoms associated with Alport syndrome in a patient in need thereof comprising administering empagliflozin to the patient.
Claims12
A method comprising:
- administering empagliflozin to a patient in order to at least one of:
- (i) treat Alport syndrome in the patient;
- (ii) improve renal function or delay or slow an impairment of the renal function in the patient diagnosed with Alport syndrome;
- (iii) delay progression of chronic kidney disease in the patient diagnosed with Alport syndrome;
- (iv) treat or alleviate glomerular hypertension in the patient diagnosed with Alport syndrome;
- (v) treat, including slowing or reversing the progression of, albuminuria and/or proteinuria in the patient diagnosed with Alport syndrome;
- (vi) improve a glomerular filtration rate or delay or slow a decline of the glomerular filtration rate in the patient diagnosed with Alport syndrome.
4 more elements
-6. (canceled)
A pharmaceutical composition comprising empagliflozin for use in a method, comprising:
- administering empagliflozin to a patient in order to at least one of:
- (i) treat Alport syndrome in the patient;
- (ii) improve renal function or delay or slow an impairment of the renal function in the patient diagnosed with Alport syndrome;
- (iii) delay progression of chronic kidney disease in the patient diagnosed with Alport syndrome;
- (iv) treat or alleviate glomerular hypertension in the patient diagnosed with Alport syndrome;
- (v) treat, including slowing or reversing the progression of, albuminuria and/or proteinuria in the patient diagnosed with Alport syndrome;
- (vi) improve a glomerular filtration rate or delay or slow a decline of the glomerular filtration rate in the patient diagnosed with Alport syndrome.
4 more elements
Dependencies are inferred from the claim text.